In this study, we performed in silico and in vitro analyses to assess the antitumor potential of two pyrazino-pyrido[2,3-d]pyrimidine-5,7-dione Series (A and B) across various cancer cell lines, focusing on possible PI3K/AKT/mTOR inhibition. This evidence concerns the gene MTOR and cancer.